| 000 | 01736 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516093212.0 | ||
| 264 | 0 | _c20130805 | |
| 008 | 201308s 0 0 eng d | ||
| 022 | _a1365-2125 | ||
| 024 | 7 |
_a10.1111/j.1365-2125.2012.04339.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTong, Gary | |
| 245 | 0 | 0 |
_aA contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat. _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _cJan 2013 |
||
| 300 |
_a136-45 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
| 650 | 0 | 4 |
_aAmyloid Precursor Protein Secretases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOxadiazoles _xadverse effects |
| 650 | 0 | 4 |
_aSulfonamides _xadverse effects |
| 700 | 1 | _aWang, Jun-Sheng | |
| 700 | 1 | _aSverdlov, Oleksandr | |
| 700 | 1 | _aHuang, Shu-Pang | |
| 700 | 1 | _aSlemmon, Randy | |
| 700 | 1 | _aCroop, Robert | |
| 700 | 1 | _aCastaneda, Lorna | |
| 700 | 1 | _aGu, Huidong | |
| 700 | 1 | _aWong, Oi | |
| 700 | 1 | _aLi, Hewei | |
| 700 | 1 | _aBerman, Robert M | |
| 700 | 1 | _aSmith, Christina | |
| 700 | 1 | _aAlbright, Charles F | |
| 700 | 1 | _aDockens, Randy | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 75 _gno. 1 _gp. 136-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2125.2012.04339.x _zAvailable from publisher's website |
| 999 |
_c21801859 _d21801859 |
||